Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Bipolar Depression
Interventions
lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
58
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
Diagnostic test (LDT)
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Iowa City, Iowa • Minneapolis, Minnesota • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced May 22, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available
Conditions
Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar II Disorder, Mental Illness
Interventions
Nicotine patch, Nicotine lozenge, Therapy, Information
Drug · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced May 22, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available
Conditions
Major Depressive Episode, Bipolar Depression, Bipolar Disorder, Mood Disorders
Interventions
NEST (NeoSync EEG Synchronized TMS)
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
52
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced May 22, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Depression
Interventions
lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced May 22, 2026, 5:38 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depressive Episode, Bipolar 1 Depression
Interventions
SEP-4199 200 mg, SEP-4199 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depression, Bipolar
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Costa Mesa, California • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Low Field Magnetic Stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Interventions
ALTO-100, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Chandler, Arizona • Phoenix, Arizona • Yuma, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced May 22, 2026, 5:38 AM EDT
Conditions
Bipolar Disorder, Major Depressive Episode
Interventions
7000lux broad-spectrum light, 50lux dim red light
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced May 22, 2026, 5:38 AM EDT